IPO Year: 2011
Exchange: NASDAQ
10-Q - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
S-8 - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
10-Q - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
S-8 - TALPHERA, INC. (0001427925) (Filer)
10-Q - TALPHERA, INC. (0001427925) (Filer)
8-K - TALPHERA, INC. (0001427925) (Filer)
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Gainers Nexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) stock moved upwards by 40.0% to $3.99. The market value of their outstanding shares is at $88.6 million. ASLAN Pharma (NASDAQ:ASLN) stock increased by 18.51% to $0.37. The market value of their outstanding shares is at $8.3 million. Talphera (NASDAQ:TLPH) shares increased by 15.18% to $0.9. The company's market cap stands at $15.2 million. Geovax Labs (NASDAQ:GOVX) stock rose 13.15% to $2.15. The market value of their outstanding shares is at $5.4 million. SAB Biotherapeutics (NASDAQ:SABS)
HC Wainwright & Co. analyst Ed Arce reiterates Talphera (NASDAQ:TLPH) with a Buy and maintains $6 price target.
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.25) by 36 percent. This is a 78.67 percent increase over losses of $(0.75) per share from the same period last year.
Maxim Group analyst Jason McCarthy initiates coverage on Talphera (NASDAQ:TLPH) with a Buy rating and announces Price Target of $3.
Gainers Clene (NASDAQ:CLNN) shares moved upwards by 54.9% to $0.48 during Tuesday's after-market session. The company's market cap stands at $61.6 million. Talphera (NASDAQ:TLPH) shares moved upwards by 11.65% to $1.15. The company's market cap stands at $19.5 million. Lexaria Bioscience (NASDAQ:LEXX) stock moved upwards by 8.22% to $2.5. The market value of their outstanding shares is at $32.2 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock increased by 7.14% to $1.8. The market value of their outstanding shares is at $2.3 million. IGC Pharma (AMEX:IGC) shares rose 6.99% to $0.52. The company's market cap stands at $34.3 million. SHL Telemedicine (NASDAQ:SHLT) stock increased by
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. Dyadic International (NASDAQ:DYAI) stock rose 21.73% to $1.68. The company's market cap stands at $48.4 million. Mesoblast (NASDAQ:MESO) shares rose 19.53% to $2.57. The company's market cap stands at $260.8 million. Aprea Therapeutics (NASDAQ:APRE) stock moved upwards by 15.28% to $8.22. The market value of their outstanding shares is at $30.7 million. Talphera (NASDAQ:TLPH) stock increased by 13.77% to $1.28. The market value of their outstanding shares is at $21.7 million. The company's, Q4 earnings came out 3 days ago.
Gainers Talphera (NASDAQ:TLPH) shares moved upwards by 15.6% to $1.3 during Friday's after-market session. The company's market cap stands at $22.0 million. As per the news, the Q4 earnings report came out 2 days ago. Genelux (NASDAQ:GNLX) shares increased by 10.06% to $7.0. The market value of their outstanding shares is at $187.0 million. Estrella Immunopharma (NASDAQ:ESLA) stock rose 8.65% to $1.13. The market value of their outstanding shares is at $41.3 million. Inspire Veterinary (NASDAQ:IVP) stock increased by 8.5% to $0.06. The market value of their outstanding shares is at $1.6 million. NRX Pharmaceuticals (NASDAQ:NRXP) shares moved upwards by 5.15% to $0.65. The market value o
Gainers Ainos (NASDAQ:AIMD) shares moved upwards by 100.0% to $2.24 during Thursday's after-market session. The market value of their outstanding shares is at $10.4 million. Talphera (NASDAQ:TLPH) stock moved upwards by 9.25% to $1.24. The market value of their outstanding shares is at $21.0 million. The company's, Q4 earnings came out yesterday. Unicycive Therapeutics (NASDAQ:UNCY) stock rose 8.66% to $1.63. The company's market cap stands at $56.6 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 7.8% to $6.49. The market value of their outstanding shares is at $4.0 million. Akili (NASDAQ:AKLI) stock increased by 7.59% to $0.34. The market value of their outstanding shares is
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update. "We're excite
SAN MATEO, Calif., Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking o
First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera as Chief Development Officer Cash and investments at March 31, 2024 of $18.6 million Conference call and webcast to be held Tuesday, May 14, 2024 at 4:30 pm ET SAN MATEO, Calif., May 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2024 financial results and provided a corporate update. "We ar
SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the w
Company rebranding and corporate transformation to Talphera completed in Q1 2024 First patient enrollment in the NEPHRO CRRT registrational study expected in Q1 2024 with a projected PMA submission by the end of 2024 Cash and investments at December 31, 2023 of $9.4 million together with the royalty and equity financings completed in January 2024 expected to provide cash runway to a potential Niyad™ approval in Q2 2025 Conference call and webcast to be held Wednesday, March 6, 2024 at 4:30 pm ET SAN MATEO, Calif., March 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therap
SAN MATEO, Calif., Feb. 26, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2023 financial results after market close on Wednesday, March 6, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com a
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
3 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
4 - TALPHERA, INC. (0001427925) (Issuer)
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors. The summit is being held on October 15-17, 2024. Event: 2024 Maxim Healthcare Virtual Summit Date: October 16, 2024 Time: 3:00 PM ET / 12:00 Noon PT Webcast link: 2024 Maxim Healthcare Virtual Summit About Talphera, Inc.Talphera, Inc. is a specialty pharmaceutical company f
SAN MATEO, Calif., Sept. 5, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in the H.C. Wainwright 26th Annual Global Investment Conference and will be taking 1x1 meetings. The conference is being held on September 9-11, 2024, at the Lotte New York Palace Hotel in New York City, and the presentation will be available on-demand starting on Monday, September 9 at 7:00 AM ET here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the we
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif., Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEP
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update. "We're excite
SAN MATEO, Calif., Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking o
SAN MATEO, Calif., May 20, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted inducement awards consisting of a non-statutory time-based stock option to purchase 185,000 shares of common stock and a time-based restricted stock unit award for 32,000 shares of common stock on May 20, 2024 to Dr. Shakil Aslam in connection with his appointment as the Chief Development Officer of Talphera in May 2024. The non-statutory stock option grant has an exercise price per shar
SAN MATEO, Calif., May 16, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET. Presentation InformationPresentation Date: Tuesday, May 21, 2024Presentation Time: 10:40 am ETFormat: Fireside Chat Webcast link: Click here About Talphera, Inc.Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervi
First patients at multiple sites are expected to be enrolled in the NEPHRO CRRT registrational study in Q2 2024 Dr. Shakil Aslam, an expert in renal diseases, including acute kidney injury, joins Talphera as Chief Development Officer Cash and investments at March 31, 2024 of $18.6 million Conference call and webcast to be held Tuesday, May 14, 2024 at 4:30 pm ET SAN MATEO, Calif., May 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2024 financial results and provided a corporate update. "We ar